{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004687","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2022-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.662688+00:00","generated_at":"2026-06-26T17:26:49.957953+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Crinetics Chief Development Officer Ajay Madan resigns effective April 1, 2022","bullets":["Ajay Madan, Ph.D., resigns as Chief Development Officer, effective April 1, 2022.","Company expects to enter a six-month consulting agreement with Madan for transition support.","Consulting retainer of approximately $37,346 per month.","No replacement named; company will search for successor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004687","json":"https://secwatch.observer/filing/0000950170-22-004687.json","markdown":"https://secwatch.observer/filing/0000950170-22-004687.md","text":"https://secwatch.observer/filing/0000950170-22-004687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/0000950170-22-004687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/crnx-20220321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T17:26:49.957953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e91176d6d9","claim":"Ajay Madan resigned as Chief Development Officer at Crinetics Pharmaceuticals, Inc..","evidence_excerpt":"On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/0000950170-22-004687-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}